Marvel Biosciences Corp (MRVL : TSX-V)
Common Stock
$0.15
CAD
-0.01 (-6.25%)
Last updated: 2026-07-23
Get MRVL alerts:
MRVL
Marvel Biosciences Corp
WealthAwesomePerformance
1 Day
-6.25%
1 Week
-6.25%
1 Month
-9.09%
YTD
+11.11%
Key Statistics
Market Cap
$9.45M
52W High
$0.40
52W Low
$0.12
P/E Ratio
-
50 Day MA
$0.17
200 Day MA
$0.16
Beta
0.59
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 7/23/2026 | $0.17 | $0.17 | $0.15 | $0.15 | $0.15 | 60,755 |
| 7/22/2026 | $0.17 | $0.17 | $0.16 | $0.16 | $0.16 | 74,440 |
| 7/21/2026 | $0.15 | $0.17 | $0.14 | $0.15 | $0.15 | 99,517 |
| 7/20/2026 | $0.15 | $0.15 | $0.14 | $0.15 | $0.15 | 58,027 |
| 7/17/2026 | $0.16 | $0.16 | $0.15 | $0.15 | $0.15 | 10,343 |
| 7/16/2026 | $0.16 | $0.16 | $0.16 | $0.16 | $0.16 | 6,408 |
| 7/15/2026 | $0.17 | $0.17 | $0.14 | $0.17 | $0.17 | 70,157 |
| 7/14/2026 | $0.15 | $0.16 | $0.15 | $0.15 | $0.15 | 74,000 |
| 7/13/2026 | $0.17 | $0.17 | $0.16 | $0.16 | $0.16 | 26,474 |
| 7/10/2026 | $0.17 | $0.17 | $0.17 | $0.17 | $0.17 | 11,002 |
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MRVL's historical volatility
30-Day Vol
118.1%
Annualized
90-Day Vol
138.6%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.13
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.14 | C$0.09 – C$0.21 |
| 60 trading days | C$0.13 | C$0.07 – C$0.24 |
| 90 trading days | C$0.13 | C$0.06 – C$0.25 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Marvel Biosciences Corp
Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company's lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer's disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hallucinogenic neuroplasticity program. The company is headquartered in Calgary, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-2.19M
- Profit Margin
- 0.00%
- ROE (TTM)
- -380.30%
- EPS (Diluted)
- -0.03
- Book Value
- -0.04
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About MRVL
Articles Featuring MRVL.V
Latest articles and analysis covering MRVL.V
Why Marvel Biosciences Corp stock is plummeting today
Marvel Biosciences Corp's stock has plummeted by 6.06% today, closing at CA$0.15. Despite promising research developments, investor sentiment seems to be faltering.
Why Marvel Biosciences Corp stock is plummeting today
Marvel Biosciences Corp's stock has taken a hit, dropping 6.06% in today's trading session. As the company navigates the complexities of drug development, investors are left questioning the stability of their investment amidst ongoing research efforts.
Why Marvel Biosciences Corp stock is skyrocketing today
Marvel Biosciences Corp's stock saw a notable increase of 6.25% today, driven by exciting developments in autism research and a forthcoming presentation at a key scientific meeting.
Why Marvel Biosciences Corp stock is skyrocketing today
Marvel Biosciences Corp (MRVL.V) has seen its stock price soar by 9.09% to CA$0.18, spurred by recent strategic developments in pediatric formulations and financial backing for its clinical trials.
What to Watch for in Marvel Biosciences' Upcoming Earnings Report
Marvel Biosciences is gearing up for its earnings report on June 17, 2026, with no EPS estimates available, raising investor curiosity about its financial health.
